Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.4.24.81 - ADAM10 endopeptidase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Abscess
Targeting Staphylococcus aureus ?-Toxin as a Novel Approach to Reduce Severity of Recurrent Skin and Soft-Tissue Infections.
Acantholysis
The involvement of ADAM10 in mucocutaneous pemphigus vulgaris acantholysis depends on the autoantibody profile in each patient.
Acute Coronary Syndrome
Soluble CLEC-2 is generated independently of ADAM10 and is increased in plasma in acute coronary syndrome: comparison with soluble GPVI.
adam 17 endopeptidase deficiency
ADAM10 and ADAM17 regulate EGFR, c-Met and TNF RI signalling in liver regeneration and fibrosis.
adam10 endopeptidase deficiency
ADAM10 and ADAM17 regulate EGFR, c-Met and TNF RI signalling in liver regeneration and fibrosis.
Adam10 Mediates the Choice between Principal Cells and Intercalated Cells in the Kidney.
ADAM10-Mediated Ectodomain Shedding Is an Essential Driver of Podocyte Damage.
Differentially regulated GPVI ectodomain shedding by multiple platelet-expressed proteinases.
Myeloid A Disintegrin and Metalloproteinase Domain 10 Deficiency Modulates Atherosclerotic Plaque Composition by Shifting the Balance from Inflammation toward Fibrosis.
Part-time alpha-secretases: the functional biology of ADAM 9, 10 and 17.
Posttranslational modifications by ADAM10 shape myeloid antigen-presenting cell homeostasis in the splenic marginal zone.
The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts.
Adenocarcinoma
A Soluble Form of the Giant Cadherin Fat1 Is Released from Pancreatic Cancer Cells by ADAM10 Mediated Ectodomain Shedding.
ADAM10 expression in gastric adenocarcinoma: Results of a curative gastrectomy cohort.
MiR-205 functions as a tumor suppressor in adenocarcinoma and an oncogene in squamous cell carcinoma of esophagus.
Albuminuria
Urinary podocyte-associated mRNA levels correlate with proximal tubule dysfunction in early diabetic nephropathy of type 2 diabetes mellitus.
Alzheimer Disease
A Connected Network of Interacting Proteins Is Involved in Human-Tau Toxicity in Drosophila.
A disintegrin and metalloproteinase (ADAM)-mediated ectodomain shedding of ADAM10.
Activation of NMDA Receptors Upregulates A Disintegrin and Metalloproteinase 10 via a Wnt/MAPK Signaling Pathway.
Activation of PPARA-mediated autophagy reduces Alzheimer disease-like pathology and cognitive decline in a murine model.
ADAM10 activation is required for green tea (-)-epigallocatechin-3-gallate-induced alpha-secretase cleavage of amyloid precursor protein.
ADAM10 as a Biomarker for Alzheimer's Disease: A Study with Brazilian Elderly.
ADAM10 as a therapeutic target for brain diseases: from developmental disorders to Alzheimer's disease.
ADAM10 expression and promoter haplotype in Alzheimer's disease.
ADAM10 gene expression in the blood cells of Alzheimer's disease patients and mild cognitive impairment subjects.
ADAM10 in Alzheimer's disease: Pharmacological modulation by natural compounds and its role as a peripheral marker.
ADAM10 Plasma and CSF Levels Are Increased in Mild Alzheimer's Disease.
ADAM10 prodomain mutations cause late-onset Alzheimer's disease: not just the latest FAD.
ADAM10 sheddase activation is controlled by cell membrane asymmetry.
ADAM9 inhibition increases membrane activity of ADAM10 and controls ?-secretase processing of amyloid precursor protein.
Alpha-secretase activation--an approach to Alzheimer's disease therapy.
Alpha-Secretase ADAM10 Regulation: Insights into Alzheimer's Disease Treatment.
Alpha-secretase as a therapeutic target.
Amyloid-? Oligomers Regulate ADAM10 Synaptic Localization Through Aberrant Plasticity Phenomena.
An arginine stretch limits ADAM10 exit from the endoplasmic reticulum.
Apolipoprotein E-mediated Modulation of ADAM10 in Alzheimer's Disease.
Artificial neural networks allow the use of simultaneous measurements of Alzheimer disease markers for early detection of the disease.
Association of ADAM10 gene variants with sporadic Parkinson's disease in Chinese Han population.
Autophagy-Dependent Increased ADAM10 Mature Protein Induced by TFEB Overexpression Is Mediated Through PPAR?.
Blocking ADAM10 synaptic trafficking generates a model of sporadic Alzheimer's disease.
Chia Seed Does Not Improve Cognitive Impairment in SAMP8 Mice Fed with High Fat Diet.
Coordinated expression of beta-amyloid precursor protein and the putative beta-secretase BACE and alpha-secretase ADAM10 in mouse and human brain.
Correlation between mini-mental state examination and platelet ADAM10 expression in Alzheimer's disease.
Cosmosiin Increases ADAM10 Expression via Mechanisms Involving 5'UTR and PI3K Signaling.
Differential gene expression in ADAM10 and mutant ADAM10 transgenic mice.
Discovery of Small Molecules for Up-Regulating the Translation of Antiamyloidogenic Secretase, a Disintegrin and Metalloproteinase 10 (ADAM10), by Binding to the G-Quadruplex-Forming Sequence in the 5' Untranslated Region (UTR) of Its mRNA.
Dyschromatosis symmetrica hereditaria and reticulate acropigmentation of Kitamura: An update.
Effect of a dominant-negative form of ADAM10 in a mouse model of Alzheimer's disease.
Effects of neuron-specific ADAM10 modulation in an in vivo model of acute excitotoxic stress.
Endocytosis of synaptic ADAM10 in neuronal plasticity and Alzheimer's disease.
Evidence against a role for rare ADAM10 mutations in sporadic Alzheimer Disease.
Extract of Caragana sinica as a potential therapeutic option for increasing alpha-secretase gene expression.
Functions of 'A disintegrin and metalloproteases (ADAMs)' in the mammalian nervous system.
Gallic Acid is a Dual ?/?-Secretase Modulator that Reverses Cognitive Impairment and Remediates Pathology in Alzheimer Mice.
GDE2-RECK controls ADAM10 ?-secretase-mediated cleavage of amyloid precursor protein.
Genetic association between ADAM10 gene polymorphism and Alzheimer's disease in a Northern Han Chinese population.
Genetic Association Between APP, ADAM10 Gene Polymorphism, and Sporadic Alzheimer's Disease in the Chinese Population.
Genomic structure and functional characterization of the human ADAM10 promoter.
Histone deacetylase inhibitor apicidin increases expression of the ?-secretase ADAM10 through transcription factor USF1-mediated mechanisms.
Identification of Phlogacantholide C as a Novel ADAM10 Enhancer from Traditional Chinese Medicinal Plants.
Increase of ?-Secretase ADAM10 in Platelets Along Cognitively Healthy Aging.
Increased CSF APPs-? levels in patients with Alzheimer disease treated with acitretin.
Influence of ADAM10 Polymorphisms on Plasma Level of Soluble Receptor for Advanced Glycation End Products and The Association With Alzheimer's Disease Risk.
Inhibitory mechanism of O-methylated quercetins, highly potent ?-secretase inhibitors isolated from Caragana balchaschensis (Kom.) Pojark.
Ionizing radiation reduces ADAM10 expression in brain microvascular endothelial cells undergoing stress-induced senescence.
Levels of ADAM10 are reduced in Alzheimer's disease CSF.
Methyl-CpG Binding Protein 2 in Alzheimer Dementia.
microRNA 221 Targets ADAM10 mRNA and is Downregulated in Alzheimer's Disease.
Nardilysin, ADAM10, and Alzheimer's disease: of mice and men.
Nasal Delivery of D-Penicillamine Hydrogel Upregulates a Disintegrin and Metalloprotease 10 Expression via Melatonin Receptor 1 in Alzheimer's Disease Models.
NrCAM is a marker for substrate-selective activation of ADAM10 in Alzheimer's disease.
Over-expression of two different forms of the alpha-secretase ADAM10 affects learning and memory in mice.
Platelet APP, ADAM 10 and BACE alterations in the early stages of Alzheimer disease.
Postnatal disruption of the disintegrin/metalloproteinase ADAM10 in brain causes epileptic seizures, learning deficits, altered spine morphology, and defective synaptic functions.
Potential late-onset Alzheimer's disease-associated mutations in the ADAM10 gene attenuate {alpha}-secretase activity.
Promoter Variants of the ADAM10 Gene and Their Roles in Temporal Lobe Epilepsy.
Protein levels of ADAM10, BACE1, and PSEN1 in platelets and leukocytes of Alzheimer's disease patients.
Quercetin stimulates the non-amyloidogenic pathway via activation of ADAM10 and ADAM17 gene expression in aluminum chloride-induced Alzheimer's disease rat model.
Reduced neuronal co-localisation of nardilysin and the putative alpha-secretases ADAM10 and ADAM17 in Alzheimer's disease and Down syndrome brains.
Regulation of ADAM10 by miR-140-5p and potential relevance for Alzheimer's disease.
Regulation of alpha-secretase ADAM10 expression and activity.
Regulation of Leukocytes by TspanC8 Tetraspanins and the "Molecular Scissor" ADAM10.
Regulation of the trafficking and the function of the metalloprotease ADAM10 by tetraspanins.
S100A7, a novel Alzheimer's disease biomarker with non-amyloidogenic alpha-secretase activity acts via selective promotion of ADAM-10.
Serotoninergic antidepressants positively affect platelet ADAM10 expression in patients with Alzheimer's disease.
SFRPs act as negative modulators of ADAM10 to regulate retinal neurogenesis.
Synaptic dysfunction in Alzheimer's disease: From the role of amyloid ?-peptide to the ?-secretase ADAM10.
Systematic substrate identification indicates a central role for the metalloprotease ADAM10 in axon targeting and synapse function.
Targeting ADAM10 to lipid rafts in neuroblastoma SH-SY5Y cells impairs amyloidogenic processing of the amyloid precursor protein.
The alpha secretase ADAM10: A metalloprotease with multiple functions in the brain.
The close link between retinoid signalling and the ?-secretase ADAM10 and its potential for treating Alzheimer's disease (commentary on Jarvis et al.).
The effect of age and obesity on platelet amyloid precursor protein processing and plasma markers of oxidative stress and inflammation.
The expression of the nicotinic acetylcholine receptor ?3 subunit in the brains of patients with Alzheimer's disease and its effects on ?- and ?-secretases and Notch signal transduction in SH-SY5Y cells.
The Role of ADAM10 in Alzheimer's Disease.
The Role of the Anti-Amyloidogenic Secretase ADAM10 in Shedding the APP-Like Proteins.
The role of the TLR4/NF-?B signaling pathway in A? accumulation in primary hippocampal neurons.
The tetraspanin Tspan15 is an essential subunit of an ADAM10 scissor complex.
The TspanC8 subgroup of tetraspanins interacts with A disintegrin and metalloprotease 10 (ADAM10) and regulates its maturation and cell surface expression.
Therapeutic impact of rHuEPO on abnormal platelet APP, BACE 1, presenilin 1, ADAM 10 and A? expressions in chronic kidney disease patients with cognitive dysfunction like Alzheimer's disease: A pilot study.
Transcriptional repression of the ectodomain sheddase ADAM10 by TBX2 and potential implication for Alzheimer's disease.
Translational repression of the disintegrin and metalloprotease ADAM10 by a stable G-quadruplex secondary structure in its 5'-untranslated region.
Unfolded protein response signaling by transcription factor XBP-1 regulates ADAM10 and is affected in Alzheimer's disease.
Variation at the ADAM10 gene locus is not associated with Creutzfeldt-Jakob disease.
Vascular endothelial growth factor improves the cognitive decline of Alzheimer's disease via concurrently inducing the expression of ADAM10 and reducing the expression of ?-site APP cleaving enzyme 1 in Tg2576 mice.
[alpha]-Secretase ADAM10 as well as [alpha]APPs is reduced in platelets and CSF of Alzheimer disease patients.
[Generation and characterization of the adult neuron-specific ADAM10 knock-out mice].
Amelogenesis Imperfecta
ADAM10 is Expressed by Ameloblasts, Cleaves the RELT TNF Receptor Extracellular Domain and Facilitates Enamel Development.
Amyloidosis
ADAM10 activation is required for green tea (-)-epigallocatechin-3-gallate-induced alpha-secretase cleavage of amyloid precursor protein.
Associations of Alzheimer's disease risk variants with gene expression, amyloidosis, tauopathy, and neurodegeneration.
Gallic Acid is a Dual ?/?-Secretase Modulator that Reverses Cognitive Impairment and Remediates Pathology in Alzheimer Mice.
YXQN Reduces Alzheimer's Disease-Like Pathology and Cognitive Decline in APPswePS1dE9 Transgenic Mice.
Anaphylaxis
ADAM10 and Notch1 on murine dendritic cells control the development of type 2 immunity and IgE production.
Aneurysm
Role of MicroRNA-103a Targeting ADAM10 in Abdominal Aortic Aneurysm.
Aortic Aneurysm, Abdominal
ADAM10 attenuates the development of abdominal aortic aneurysms in a mouse model.
Proteolytically active ADAM10 and ADAM17 carried on membrane microvesicles in human abdominal aortic aneurysms.
Role of MicroRNA-103a Targeting ADAM10 in Abdominal Aortic Aneurysm.
Aortic Aneurysm, Thoracic
Elevation of ADAM10, ADAM17, MMP-2 and MMP-9 expression with media degeneration features CaCl2-induced thoracic aortic aneurysm in a rat model.
Arthritis
Genetic loci that regulate ectopic calcification in response to knee trauma in LG/J by SM/J advanced intercross mice.
Knockdown of ADAM10 inhibits migration and invasion of fibroblast-like synoviocytes in rheumatoid arthritis.
MiR-20a inhibits the progression of human arthritis fibroblast-like synoviocytes and inflammatory factor expression by targeting ADAM10.
Arthritis, Rheumatoid
A disintegrin and metalloprotease-10 is correlated with disease activity and mediates monocyte migration and adhesion in rheumatoid arthritis.
ADAM-10 is overexpressed in rheumatoid arthritis synovial tissue and mediates angiogenesis.
Knockdown of ADAM10 inhibits migration and invasion of fibroblast-like synoviocytes in rheumatoid arthritis.
miR?152 inhibits rheumatoid arthritis synovial fibroblast proliferation and induces apoptosis by targeting ADAM10.
[Retracted] miR?152 inhibits rheumatoid arthritis synovial fibroblast proliferation and induces apoptosis by targeting ADAM10.
Asthma
A potential new target for asthma therapy: A Disintegrin and Metalloprotease 10 (ADAM10) involvement in murine experimental asthma.
ADAM-family metalloproteinases in lung inflammation: potential therapeutic targets.
Regulation of Leukocytes by TspanC8 Tetraspanins and the "Molecular Scissor" ADAM10.
Scissor sisters: regulation of ADAM10 by the TspanC8 tetraspanins.
The xenoestrogens biphenol-A and nonylphenol differentially regulate metalloprotease-mediated shedding of EGFR ligands.
Astrocytoma
The effects of alpha-secretase ADAM10 on the proteolysis of neuregulin-1.
Atherosclerosis
A disintegrin and metalloprotease 10 is a novel mediator of vascular endothelial growth factor-induced endothelial cell function in angiogenesis and is associated with atherosclerosis.
A Disintegrin and Metalloproteases (ADAMs) in Cardiovascular, Metabolic and Inflammatory Diseases: Aspects for Theranostic Approaches.
An Association Study on ADAM10 Promoter Polymorphisms and Atherosclerotic Cerebral Infarction in a Chinese Population.
Expression and cellular localization of metalloproteases ADAMs in high graded carotid artery lesions.
LncRNA ZFAS1 confers inflammatory responses and reduces cholesterol efflux in atherosclerosis through regulating miR-654-3p-ADAM10/RAB22A axis.
Long non-coding RNA CDKN2B-AS1 reduces inflammatory response and promotes cholesterol efflux in atherosclerosis by inhibiting ADAM10 expression.
miR-21-3p regulates AGE/RAGE signalling and improves diabetic atherosclerosis.
Myeloid A Disintegrin and Metalloproteinase Domain 10 Deficiency Modulates Atherosclerotic Plaque Composition by Shifting the Balance from Inflammation toward Fibrosis.
Autoimmune Diseases
The association of clinical phenotypes to known AD/FTD genetic risk loci and their inter-relationship.
Bacterial Infections
Scissor sisters: regulation of ADAM10 by the TspanC8 tetraspanins.
Blister
ADAM10-mediated E-cadherin release is regulated by proinflammatory cytokines and modulates keratinocyte cohesion in eczematous dermatitis.
Brain Diseases
ADAM10 as a therapeutic target for brain diseases: from developmental disorders to Alzheimer's disease.
The alpha secretase ADAM10: A metalloprotease with multiple functions in the brain.
Brain Injuries
Pharmacologic Inhibition of ADAM10 Attenuates Brain Tissue Loss, Axonal Injury and Pro-inflammatory Gene Expression Following Traumatic Brain Injury in Mice.
Brain Injuries, Traumatic
MiR-144 promotes ?-amyloid accumulation-induced cognitive impairments by targeting ADAM10 following traumatic brain injury.
MT5-MMP, ADAM-10, and N-cadherin act in concert to facilitate synapse reorganization after traumatic brain injury.
Pharmacologic Inhibition of ADAM10 Attenuates Brain Tissue Loss, Axonal Injury and Pro-inflammatory Gene Expression Following Traumatic Brain Injury in Mice.
Plasma PrPC and ADAM-10 as novel biomarkers for traumatic brain injury and concussion: a pilot study.
Brain Neoplasms
Drug Blocks Synaptic Hijacking in Gliomas.
Breast Neoplasms
ADAM10 is involved in the oncogenic process and chemo-resistance of triple-negative breast cancer via regulating Notch1 signaling pathway, CD44 and PrPc.
ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer.
ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angiogenic properties.
ADAM10: a new player in breast cancer progression?
ADAM9 inhibition increases membrane activity of ADAM10 and controls ?-secretase processing of amyloid precursor protein.
Diallyl trisulfide, a chemopreventive agent from Allium vegetables, inhibits alpha-secretases in breast cancer cells.
Discovery of an enzyme and substrate selective inhibitor of ADAM10 using an exosite-binding glycosylated substrate.
Effects of ADAM10 and ADAM17 Inhibitors on Natural Killer Cell Expansion and Antibody-dependent Cellular Cytotoxicity Against Breast Cancer Cells
Elevated serum HER-2 predicts poor prognosis in breast cancer and is correlated to ADAM10 expression.
Endostatin and irradiation modifies the activity of ADAM10 and neprilysin in breast cancer cells.
Fas/FasL-dependent and -independent activation of caspase-8 in doxorubicin-treated human breast cancer MCF-7 cells: ADAM10 down-regulation activates Fas/FasL signaling pathway.
How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study.
Human mesenchymal stem cells induce E-cadherin degradation in breast carcinoma spheroids by activating ADAM10.
Identification of ADAM10 as a Major Source of HER2 Ectodomain Sheddase Activity in HER2 Overexpressing Breast Cancer Cells.
Increased expression of ADAM family members in human breast cancer and breast cancer cell lines.
Loss of the Timp gene family is sufficient for the acquisition of the CAF-like cell state.
Low-volume multiplexed proteolytic activity assay and inhibitor analysis through a pico-injector array.
Mesenchymal stem cells: "repair cells" that serve wounds and cancer?
miR-365 inhibits cell invasion and migration of triple negative breast cancer through ADAM10.
MiR-891a-5p as a prognostic marker and therapeutic target for hormone receptor-positive breast cancer.
Novel role of APP cleavage by ADAM10 for breast cancer metastasis.
Proteolytic cleavage of amyloid precursor protein by ADAM10 mediates proliferation and migration in breast cancer.
Thalidomide combined with irradiation alters the activity of two proteases.
The association of the expression of miR-122-5p and its target ADAM10 with human breast cancer.
The xenoestrogens biphenol-A and nonylphenol differentially regulate metalloprotease-mediated shedding of EGFR ligands.
Triptolide: An inhibitor of a disintegrin and metalloproteinase 10 (ADAM10) in cancer cells.
Candidiasis
IL-1{beta} and ADAM17 are central regulators of {beta}-defensin expression in Candida esophagitis.
Carcinogenesis
ADAM10 mediates the cell invasion and metastasis of human esophageal squamous cell carcinoma via regulation of E-cadherin activity.
ADAM10 sheddase activation is controlled by cell membrane asymmetry.
CXCL16 Promotes Gastric Cancer Tumorigenesis via ADAM10-Dependent CXCL16/CXCR6 Axis and Activates Akt and MAPK Signaling Pathways.
Increase of disintergin metalloprotease 10 (ADAM10) expression in oral squamous cell carcinoma.
MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to Sorafenib.
N-Cadherin, ADAM-10 and Aquaporin 1 expression in lung tissue exposed to fluoro-edenite fibers: an immunohistochemical study.
Role of ADAM10 in intestinal crypt homeostasis and tumorigenesis.
Tetraspanin CD9 interacts with ?-secretase to enhance its oncogenic function in pancreatic cancer.
Triptolide: An inhibitor of a disintegrin and metalloproteinase 10 (ADAM10) in cancer cells.
Upregulated expression levels of ADAM10 and EGFR and downregulated expression levels of E-cadherin in hepatocellular carcinomas.
Carcinoma
Activation of microRNA-494-targeting Bmi1 and ADAM10 by silibinin ablates cancer stemness and predicts favourable prognostic value in head and neck squamous cell carcinomas.
ADAM 10 is over expressed in oral squamous cell carcinoma and contributes to invasive behaviour through a functional association with ?v?6 integrin.
ADAM10 expression in gastric adenocarcinoma: Results of a curative gastrectomy cohort.
ADAM10 mediates the cell invasion and metastasis of human esophageal squamous cell carcinoma via regulation of E-cadherin activity.
ADAMs (a disintegrin and metalloproteinase) messenger RNA expression in Helicobacter pylori-infected, normal, and neoplastic gastric mucosa.
Clinical significance of ADAM10 expression in laryngeal carcinoma.
Effect of A disintegrin and metalloproteinase 10 gene silencing on the proliferation, invasion and migration of the human tongue squamous cell carcinoma cell line TCA8113.
Expression of A disintegrin and metalloprotease 10 in pancreatic carcinoma.
Expression of ADAM10, Fas, FasL and Soluble FasL in Patients with Oral Squamous Cell Carcinoma (OSCC) and their Association with Clinical-Pathological Parameters.
Inhibiting adenoid cystic carcinoma cells growth and metastasis by blocking the expression of ADAM 10 using RNA interference.
MiR-205 functions as a tumor suppressor in adenocarcinoma and an oncogene in squamous cell carcinoma of esophagus.
MiR-449a regulates the cell migration and invasion of human non-small cell lung carcinoma by targeting ADAM10.
Nuclear translocation and signaling of L1-CAM in human carcinoma cells requires ADAM10 and presenilin/gamma-secretase activity.
Overexpression of A disintegrin and metalloprotease 10 promotes tumor proliferation, migration and poor prognosis in hypopharyngeal squamous cell carcinoma.
Overexpression of ADAM10 in oral squamous cell carcinoma with metastases.
Reciprocal effects between microRNA-140-5p and ADAM10 suppress migration and invasion of human tongue cancer cells.
Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding.
The disintegrin-metalloproteinases ADAM 10, 12 and 17 are upregulated in invading peripheral tumor cells of basal cell carcinomas.
The disintegrin-metalloproteinases ADAM10 and ADAM17 are upregulated in cutaneous squamous cell carcinomas.
The transcription factor PAX2 regulates ADAM10 expression in renal cell carcinoma.
Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients.
Upregulation of ADAM10 in oral squamous cell carcinoma and its correlation with EGFR, neoangiogenesis and clinicopathologic factors.
[miR-140-5p affects the migration and invasion of hypopharyngeal carcinoma cells by downregulating ADAM10 expression].
Carcinoma, Adenoid Cystic
Inhibiting adenoid cystic carcinoma cells growth and metastasis by blocking the expression of ADAM 10 using RNA interference.
Carcinoma, Basal Cell
The disintegrin-metalloproteinases ADAM 10, 12 and 17 are upregulated in invading peripheral tumor cells of basal cell carcinomas.
Carcinoma, Hepatocellular
ADAM10 is overexpressed in human hepatocellular carcinoma and contributes to the proliferation, invasion and migration of HepG2 cells.
ADAM10 overexpression confers resistance to doxorubicin-induced apoptosis in hepatocellular carcinoma.
Anticancer Chemotherapy Inhibits MHC Class I-Related Chain A Ectodomain Shedding by Downregulating ADAM10 Expression in Hepatocellular Carcinoma.
Downregulation of ADAM10 Expression Inhibits Metastasis and Invasiveness of Human Hepatocellular Carcinoma HepG2 Cells.
Human umbilical cord mesenchymal stem cells-derived exosomal microRNA-451a represses epithelial-mesenchymal transition of hepatocellular carcinoma cells by inhibiting ADAM10.
Impact of ADAM10 gene polymorphisms on hepatocellular carcinoma development and clinical characteristics.
Knockout of ADAM10 enhances sorafenib antitumor activity of hepatocellular carcinoma in vitro and in vivo.
Long noncoding LINC01551 promotes hepatocellular carcinoma cell proliferation, migration, and invasion by acting as a competing endogenous RNA of microRNA-122-5p to regulate ADAM10 expression.
MicroRNA-655-3p functions as a tumor suppressor by regulating ADAM10 and ?-catenin pathway in Hepatocellular Carcinoma.
miR-365 targets ADAM10 and suppresses the cell growth and metastasis of hepatocellular carcinoma.
miR-449a inhibits proliferation and invasion by regulating ADAM10 in hepatocellular carcinoma.
Novel therapeutic features of disulfiram against hepatocellular carcinoma cells with inhibitory effects on a disintegrin and metalloproteinase 10.
Retracted: Downregulation of ADAM10 expression inhibits metastasis and invasiveness of human hepatocellular carcinoma HepG2 cells.
Retraction.
Silencing ADAM10 inhibits the in vitro and in vivo growth of hepatocellular carcinoma cancer cells.
Synergistic effects of co-expression plasmid?based ADAM10-specific siRNA and GRIM-19 on hepatocellular carcinoma in vitro and in vivo.
Upregulated expression levels of ADAM10 and EGFR and downregulated expression levels of E-cadherin in hepatocellular carcinomas.
Carcinoma, Non-Small-Cell Lung
ADAM10 overexpression in human non-small cell lung cancer correlates with cell migration and invasion through the activation of the Notch1 signaling pathway.
CircNFIX Acts as a miR-212-3p Sponge to Enhance the Malignant Progression of Non-Small Cell Lung Cancer by Up-Regulating ADAM10.
MiR-449a regulates the cell migration and invasion of human non-small cell lung carcinoma by targeting ADAM10.
Carcinoma, Papillary
Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients.
Carcinoma, Renal Cell
Suppression of tunicamycin-induced CD44v6 ectodomain shedding and apoptosis is correlated with temporal expression patterns of active ADAM10, MMP-9 and MMP-13 proteins in Caki-2 renal carcinoma cells.
The transcription factor PAX2 regulates ADAM10 expression in renal cell carcinoma.
Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients.
Carcinoma, Squamous Cell
Activation of microRNA-494-targeting Bmi1 and ADAM10 by silibinin ablates cancer stemness and predicts favourable prognostic value in head and neck squamous cell carcinomas.
Effect of A disintegrin and metalloproteinase 10 gene silencing on the proliferation, invasion and migration of the human tongue squamous cell carcinoma cell line TCA8113.
MiR-205 functions as a tumor suppressor in adenocarcinoma and an oncogene in squamous cell carcinoma of esophagus.
Reciprocal effects between microRNA-140-5p and ADAM10 suppress migration and invasion of human tongue cancer cells.
Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding.
The disintegrin-metalloproteinases ADAM10 and ADAM17 are upregulated in cutaneous squamous cell carcinomas.
Cardiomyopathies
Interrelation between Expression of ADAM 10 and MMP 9 and Synthesis of Peroxynitrite in Doxorubicin Induced Cardiomyopathy.
[Improvement and the mechanism of cardiac function by knockdown of ADAM10 in adriamycin-induced cardiomyopathy rats].
Cardiomyopathy, Dilated
Altered expression of disintegrin metalloproteinases and their inhibitor in human dilated cardiomyopathy.
Cardiovascular Diseases
Ionising radiation increases permeability of endothelium through ADAM10-mediated cleavage of VE-cadherin.
Regulation of the trafficking and the function of the metalloprotease ADAM10 by tetraspanins.
Central Nervous System Diseases
ADAM10 suppresses demyelination and reduces seizure susceptibility in cuprizone-induced demyelination model.
Cerebral Amyloid Angiopathy
Ionizing radiation reduces ADAM10 expression in brain microvascular endothelial cells undergoing stress-induced senescence.
Cerebral Infarction
An Association Study on ADAM10 Promoter Polymorphisms and Atherosclerotic Cerebral Infarction in a Chinese Population.
Chlamydophila Infections
Astrocytes infected with Chlamydia pneumoniae demonstrate altered expression and activity of secretases involved in the generation of ?-amyloid found in Alzheimer disease.
Chordoma
ADAM10 Is a Potential Novel Prognostic Biomarker for Sacral Chordoma.
Colonic Neoplasms
Cell fusion promotes chemoresistance in metastatic colon carcinoma.
Expression of L1-CAM and ADAM10 in human colon cancer cells induces metastasis.
Trop-2 induces ADAM10-mediated cleavage of E-cadherin and drives EMT-less metastasis in colon cancer.
Colorectal Neoplasms
Adamalysines as Biomarkers and a Potential Target of Therapy in Colorectal Cancer Patients: Preliminary Results.
L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers.
Relation between Tetraspanin- Associated and Tetraspanin- Non- Associated Exosomal Proteases and Metabolic Syndrome in Colorectal Cancer Patients
Serological immune response against ADAM10 pro-domain is associated with favourable prognosis in stage III colorectal cancer patients.
Serum levels of ADAM10, ADAM12, ADAM17 AND ADAM28 in colorectal cancer patients.
Soluble Receptor for Advanced Glycation End-products (sRAGE) and Colorectal Cancer Risk: A Case-Control Study Nested within a European Prospective Cohort.
Creutzfeldt-Jakob Syndrome
TREM2 expression in the brain and biological fluids in prion diseases.
Variation at the ADAM10 gene locus is not associated with Creutzfeldt-Jakob disease.
[Genetic background of human prion diseases]
Cysts
ADAM10-Notch signaling governs the recruitment of ovarian pregranulosa cells and controls folliculogenesis in mice.
The disintegrin/metalloproteinase Adam10 is essential for epidermal integrity and Notch-mediated signaling.
Dementia
Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A?, tau, immunity and lipid processing.
Methylomic profiling in trisomy 21 identifies cognition- and Alzheimer's disease-related dysregulation.
Platelets: Peripheral Biomarkers of Dementia?
Demyelinating Diseases
ADAM10 suppresses demyelination and reduces seizure susceptibility in cuprizone-induced demyelination model.
Cornel Iridoid Glycoside Ameliorated Alzheimer's Disease-Like Pathologies and Necroptosis through RIPK1/MLKL Pathway in Young and Aged SAMP8 Mice.
N-cadherin promotes recruitment and migration of neural progenitor cells from the SVZ neural stem cell niche into demyelinated lesions.
Dermatomyositis
The cell-specific expression of metalloproteinase-disintegrins (ADAMs) in inflammatory myopathies.
Diabetes Mellitus, Type 1
Serum Level of Soluble Receptor for Advanced Glycation End Products Is Associated with A Disintegrin And Metalloproteinase 10 in Type 1 Diabetes.
Diabetic Nephropathies
CXCL16 and oxLDL are induced in the onset of diabetic nephropathy.
Urinary podocyte-associated mRNA levels correlate with proximal tubule dysfunction in early diabetic nephropathy of type 2 diabetes mellitus.
Diabetic Retinopathy
Evaluation of Proteoforms of the Transmembrane Chemokines CXCL16 and CX3CL1, Their Receptors, and Their Processing Metalloproteinases ADAM10 and ADAM17 in Proliferative Diabetic Retinopathy.
Down Syndrome
Reduced neuronal co-localisation of nardilysin and the putative alpha-secretases ADAM10 and ADAM17 in Alzheimer's disease and Down syndrome brains.
Eczema
ADAM10-mediated E-cadherin release is regulated by proinflammatory cytokines and modulates keratinocyte cohesion in eczematous dermatitis.
Encephalitis
Gallic Acid is a Dual ?/?-Secretase Modulator that Reverses Cognitive Impairment and Remediates Pathology in Alzheimer Mice.
Involvement of IRS-1 Interaction with ADAM10 in the Regulation of Neurite Extension.
Endometriosis
ADAM-10 and -17 regulate endometriotic cell migration via concerted ligand and receptor shedding feedback on kinase signaling.
Eosinophilia
A potential new target for asthma therapy: A Disintegrin and Metalloprotease 10 (ADAM10) involvement in murine experimental asthma.
Epilepsy
Metalloprotease Adam10 suppresses epilepsy through repression of hippocampal neuroinflammation.
Promoter Variants of the ADAM10 Gene and Their Roles in Temporal Lobe Epilepsy.
Regulation of ADAM10 by MicroRNA-23a Contributes to Epileptogenesis in Pilocarpine-Induced Status Epilepticus Mice.
Stage-dependent involvement of ADAM10 and its significance in epileptic seizures.
The alpha secretase ADAM10: A metalloprotease with multiple functions in the brain.
Epilepsy, Temporal Lobe
Promoter Variants of the ADAM10 Gene and Their Roles in Temporal Lobe Epilepsy.
Regulation of ADAM10 by MicroRNA-23a Contributes to Epileptogenesis in Pilocarpine-Induced Status Epilepticus Mice.
Epiretinal Membrane
Evaluation of Proteoforms of the Transmembrane Chemokines CXCL16 and CX3CL1, Their Receptors, and Their Processing Metalloproteinases ADAM10 and ADAM17 in Proliferative Diabetic Retinopathy.
Esophageal Neoplasms
ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3.
Esophageal Squamous Cell Carcinoma
ADAM10 mediates the cell invasion and metastasis of human esophageal squamous cell carcinoma via regulation of E-cadherin activity.
Fibrosarcoma
Janus kinase 2 influences growth hormone receptor metalloproteolysis.
Fragile X Syndrome
The alpha secretase ADAM10: A metalloprotease with multiple functions in the brain.
Gastritis
ADAM proteases involved in inflammation are differentially altered in patients with gastritis or ulcer.
Glioblastoma
ADAM-10 could mediate cleavage of N-cadherin promoting apoptosis in human atherosclerotic lesions leading to vulnerable plaque: A morphological and immunohistochemical study.
Characterization of matrix metalloproteinase-2 and -9, ADAM-10 and N-cadherin expression in human glioblastoma multiforme.
Metalloproteinases ADAM10 and ADAM17 Mediate Migration and Differentiation in Glioblastoma Sphere-Forming Cells.
Glioma
A-Disintegrin and Metalloprotease (ADAM) 10 and 17 promote self-renewal of brain tumor sphere forming cells.
Expression of a-disintegrin and metalloproteinase 10 correlates with grade of malignancy in human glioma.
Glioma-derived ADAM10 induces regulatory B cells to suppress CD8+ T cells.
L1 stimulation of human glioma cell motility correlates with FAK activation.
L1CAM stimulates glioma cell motility and proliferation through the fibroblast growth factor receptor.
NLGN3 Upregulates Expression of ADAM10 to Promote the Cleavage of NLGN3 via Activating the LYN Pathway in Human Gliomas.
Glomerulonephritis, IGA
ADAM10 mediates ectopic proximal tubule development and renal fibrosis through Notch signalling.
HIV Infections
Pharmacogenomics study on cadherin 2 network with regard to HIV infection and methadone treatment outcome.
Soluble T Cell Immunoglobulin Mucin Domain 3 Is Shed from CD8+ T Cells by the Sheddase ADAM10, Is Increased in Plasma during Untreated HIV Infection, and Correlates with HIV Disease Progression.
Hodgkin Disease
ADAM10 new selective inhibitors reduce NKG2D ligand release sensitizing Hodgkin lymphoma cells to NKG2D-mediated killing.
Discovery of a new selective inhibitor of A Disintegrin And Metalloprotease 10 (ADAM-10) able to reduce the shedding of NKG2D ligands in Hodgkin's lymphoma cell models.
Inhibitors of A Disintegrin And Metalloproteinases-10 reduce Hodgkin lymphoma cell growth in 3D microenvironments and enhance brentuximab-vedotin effect.
Role of ADAM10 as a CD30 Sheddase in Classical Hodgkin Lymphoma.
Specific ADAM10 inhibitors localize in exosome-like vesicles released by Hodgkin lymphoma and stromal cells and prevent sheddase activity carried to bystander cells.
Huntington Disease
ADAM10 hyperactivation acts on piccolo to deplete synaptic vesicle stores in Huntington's disease.
Inhibiting pathologically active ADAM10 rescues synaptic and cognitive decline in Huntington's disease.
The alpha secretase ADAM10: A metalloprotease with multiple functions in the brain.
Hydronephrosis
Adam10 Mediates the Choice between Principal Cells and Intercalated Cells in the Kidney.
Hyperalgesia
Neuron-Derived ADAM10 Production Stimulates Peripheral Nerve Injury-Induced Neuropathic Pain by Cleavage of E-Cadherin in Satellite Glial Cells.
Hypersensitivity
ADAM10 is a principal 'sheddase' of the low-affinity immunoglobulin E receptor CD23.
Increased B Cell ADAM10 in Allergic Patients and Th2 Prone Mice.
Regulation of Leukocytes by TspanC8 Tetraspanins and the "Molecular Scissor" ADAM10.
Infections
A Staphylococcus aureus pore-forming toxin subverts the activity of ADAM10 to cause lethal infection in mice.
ADAMs (a disintegrin and metalloproteinase) messenger RNA expression in Helicobacter pylori-infected, normal, and neoplastic gastric mucosa.
Analysis of cell hyperplasia and parietal cell dysfunction induced by Ostertagia ostertagi infection.
Apparent Reduction of ADAM10 in Scrapie-Infected Cultured Cells and in the Brains of Scrapie-Infected Rodents.
Astrocytes infected with Chlamydia pneumoniae demonstrate altered expression and activity of secretases involved in the generation of ?-amyloid found in Alzheimer disease.
Dissecting the role of ADAM10 as a mediator of Staphylococcus aureus ?-toxin action.
Genetic Requirement for ADAM10 in Severe Staphylococcus aureus Skin Infection.
Influence of ADAM10 on prion protein processing and scrapie infectiosity in vivo.
Myeloid-derived suppressor cells enhance IgE-mediated mast cell responses.
Targeting Staphylococcus aureus ?-Toxin as a Novel Approach to Reduce Severity of Recurrent Skin and Soft-Tissue Infections.
The sheddase ADAM10 is a potent modulator of prion disease.
The shedding-derived soluble receptor for advanced glycation endproducts sustains inflammation during acute Pseudomonas aeruginosa lung infection.
Tissue-specific patterning of host innate immune responses by Staphylococcus aureus ?-toxin.
Vaccinia virus hijacks EGFR signalling to enhance virus spread through rapid and directed infected cell motility.
Infertility
Endothelial deletion of ADAM10, a key regulator of Notch signaling, causes impaired decidualization and reduced fertility in female mice.
Influenza, Human
ADAM10 Partially Protects Mice against Influenza Pneumonia by Suppressing Specific Myeloid Cell Population.
Insulin Resistance
Metabolic profiling distinguishes three subtypes of Alzheimer's disease.
Intussusception
Glomerular endothelial cell maturation depends on ADAM10, a key regulator of Notch signaling.
Iron Overload
The Effect of TCM-Induced HAMP on Key Enzymes in the Hydrolysis of AD Model Cells.
Kidney Diseases
ADAM10 is expressed in human podocytes and found in urinary vesicles of patients with glomerular kidney diseases.
Characterization of CXCL16 and ADAM10 in the normal and transplanted kidney.
CXCL16 Is Expressed in Podocytes and Acts as a Scavenger Receptor for Oxidized Low-Density Lipoprotein.
Kidney Failure, Chronic
Association of CD30 transcripts with Th1 responses and proinflammatory cytokines in patients with end-stage renal disease.
Kidney Neoplasms
Human renal cancer cells express a novel membrane-bound interleukin-15 that induces, in response to the soluble interleukin-15 receptor alpha chain, epithelial-to-mesenchymal transition.
The transcription factor PAX2 regulates ADAM10 expression in renal cell carcinoma.
Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients.
Leukemia
A disintegrin and metalloprotease-10 is correlated with disease activity and mediates monocyte migration and adhesion in rheumatoid arthritis.
An ADAM10 promoter polymorphism is a functional variant in severe sepsis patients and confers susceptibility to the development of sepsis.
Selective use of ADAM10 and ADAM17 in activation of Notch1 signaling.
The low affinity IgE receptor (CD23) is cleaved by the metalloproteinase ADAM10.
Triptolide: An inhibitor of a disintegrin and metalloproteinase 10 (ADAM10) in cancer cells.
[Effect of ADAM10 Inhibitor GI254023X on Proliferation and Apoptosis of Acute T-Lymphoblastic Leukemia Jurkat Cells In Vitro and Its Possible Mechanisms].
Leukemia, Monocytic, Acute
An ADAM10 promoter polymorphism is a functional variant in severe sepsis patients and confers susceptibility to the development of sepsis.
Leukoplakia, Oral
Overexpression of ADAM10 in oral squamous cell carcinoma with metastases.
Liver Cirrhosis
ADAM10 and ADAM17 regulate EGFR, c-Met and TNF RI signalling in liver regeneration and fibrosis.
CX3CL1/FRACTALKINE SHEDDING BY HUMAN HEPATIC STELLATE CELLS: CONTRIBUTION TO CHRONIC INFLAMMATION IN THE LIVER.
Liver Diseases
CX3CL1/FRACTALKINE SHEDDING BY HUMAN HEPATIC STELLATE CELLS: CONTRIBUTION TO CHRONIC INFLAMMATION IN THE LIVER.
Liver Neoplasms
Computational identification and experimental validation of microRNAs binding to the Alzheimerrelated gene ADAM10.
Knockout of ADAM10 enhances sorafenib antitumor activity of hepatocellular carcinoma in vitro and in vivo.
Lung Neoplasms
ADAM10 overexpression in human non-small cell lung cancer correlates with cell migration and invasion through the activation of the Notch1 signaling pathway.
CircNFIX Acts as a miR-212-3p Sponge to Enhance the Malignant Progression of Non-Small Cell Lung Cancer by Up-Regulating ADAM10.
Platelet-mediated shedding of NKG2D ligands impairs NK cell immune-surveillance of tumor cells.
Lymphatic Metastasis
ADAM10 mediates the cell invasion and metastasis of human esophageal squamous cell carcinoma via regulation of E-cadherin activity.
Impact of ADAM10 gene polymorphisms on hepatocellular carcinoma development and clinical characteristics.
Overexpression of A disintegrin and metalloprotease 10 promotes tumor proliferation, migration and poor prognosis in hypopharyngeal squamous cell carcinoma.
Lymphoma
Constitutive activation of metalloproteinase ADAM10 in mantle cell lymphoma promotes cell growth and activates the TNF{alpha}/NF{kappa}B pathway.
High ERp5/ADAM10 expression in lymph node microenvironment and impaired NKG2D ligands recognition in Hodgkin lymphomas.
Inhibitors of A Disintegrin And Metalloproteinases-10 reduce Hodgkin lymphoma cell growth in 3D microenvironments and enhance brentuximab-vedotin effect.
Specific ADAM10 inhibitors localize in exosome-like vesicles released by Hodgkin lymphoma and stromal cells and prevent sheddase activity carried to bystander cells.
Lymphoma, Mantle-Cell
Constitutive activation of metalloproteinase ADAM10 in mantle cell lymphoma promotes cell growth and activates the TNF{alpha}/NF{kappa}B pathway.
Malformations of Cortical Development
Stage-dependent involvement of ADAM10 and its significance in epileptic seizures.
Melanoma
ADAM 10 expression in primary uveal melanoma as prognostic factor for risk of metastasis.
ADAM10 correlates with uveal melanoma metastasis and promotes in vitro invasion.
ADAM10 is the constitutive functional sheddase of CD44 in human melanoma cells.
ADAM10 Is Upregulated in Melanoma Metastasis Compared with Primary Melanoma.
High percentage of ADAM-10 positive melanoma cells correlates with paucity of tumor-infiltrating lymphocytes but does not predict prognosis in cutaneous melanoma patients.
HIV Nef, Paxillin, and Pak1/2 Regulate Activation and Secretion of TACE/ADAM10 Proteases.
Noncanonical Activation of Notch1 Protein by Membrane Type 1 Matrix Metalloproteinase (MT1-MMP) Controls Melanoma Cell Proliferation.
PAX2 Regulates ADAM10 Expression and Mediates Anchorage-Independent Cell Growth of Melanoma Cells.
Potential Onco-Suppressive Role of miR122 and miR144 in Uveal Melanoma through ADAM10 and C-Met Inhibition.
Shedding light on proteolytic cleavage of CD44: the responsible sheddase and functional significance of shedding.
The glycoprotein GPNMB attenuates astrocyte inflammatory responses through the CD44 receptor.
Memory Disorders
Identification of disulfiram as a secretase-modulating compound with beneficial effects on Alzheimer's disease hallmarks.
Mesothelioma
ADAM10 mediates malignant pleural mesothelioma invasiveness.
Mesothelioma, Malignant
ADAM10 mediates malignant pleural mesothelioma invasiveness.
Mouth Neoplasms
Overexpression of ADAM10 in oral squamous cell carcinoma with metastases.
Multiple Myeloma
[Effect of ADAM10 Inhibitor GI254023X on Proliferation and Apoptosis of Multiple Myeloma H929 Cells and Its Possible Mechanisms].
[Effect of Interfering the ADAM10 by Lentivirul Vector-Mediated shRNA on Multiple Myeloma MM.1S Cell Proliferation].
Multiple Sclerosis
ADAM10 suppresses demyelination and reduces seizure susceptibility in cuprizone-induced demyelination model.
Myeloproliferative Disorders
Dual functions of cell-autonomous and non-cell-autonomous ADAM10 activity in granulopoiesis.
Regulation of adult hematopoiesis by the a disintegrin and metalloproteinase 10 (ADAM10).
Myocardial Infarction
Common variation in the ADAM8 gene affects serum sADAM8 concentrations and the risk of myocardial infarction in two independent cohorts.
Scissor sisters: regulation of ADAM10 by the TspanC8 tetraspanins.
Myositis
The cell-specific expression of metalloproteinase-disintegrins (ADAMs) in inflammatory myopathies.
Myositis, Inclusion Body
The cell-specific expression of metalloproteinase-disintegrins (ADAMs) in inflammatory myopathies.
Nasal Polyps
Expression of ADAM17 and ADAM10 in nasal polyps.
Nasopharyngeal Carcinoma
Effects of ADAM10 upregulation on progression, migration, and prognosis of nasopharyngeal carcinoma.
Neoplasm Metastasis
Activation of MMP-9 by membrane type-1 MMP/MMP-2 axis stimulates tumor metastasis.
ADAM 10 expression in primary uveal melanoma as prognostic factor for risk of metastasis.
ADAM 10 is associated with gastric cancer progression and prognosis of patients.
ADAM10 correlates with uveal melanoma metastasis and promotes in vitro invasion.
ADAM10 Is a Potential Novel Prognostic Biomarker for Sacral Chordoma.
ADAM10 Is Upregulated in Melanoma Metastasis Compared with Primary Melanoma.
ADAM10 mediates the cell invasion and metastasis of human esophageal squamous cell carcinoma via regulation of E-cadherin activity.
ADAM10 overexpression in human non-small cell lung cancer correlates with cell migration and invasion through the activation of the Notch1 signaling pathway.
Adamalysines as Biomarkers and a Potential Target of Therapy in Colorectal Cancer Patients: Preliminary Results.
Downregulation of ADAM10 Expression Inhibits Metastasis and Invasiveness of Human Hepatocellular Carcinoma HepG2 Cells.
Effects of ADAM10 upregulation on progression, migration, and prognosis of nasopharyngeal carcinoma.
Expression of A disintegrin and metalloprotease 10 in pancreatic carcinoma.
Expression of L1-CAM and ADAM10 in human colon cancer cells induces metastasis.
Fendiline inhibits proliferation and invasion of pancreatic cancer cells by interfering with ADAM10 activation and ?-catenin signaling.
High percentage of ADAM-10 positive melanoma cells correlates with paucity of tumor-infiltrating lymphocytes but does not predict prognosis in cutaneous melanoma patients.
Impact of ADAM10 gene polymorphisms on hepatocellular carcinoma development and clinical characteristics.
Inhibiting adenoid cystic carcinoma cells growth and metastasis by blocking the expression of ADAM 10 using RNA interference.
Long Non-Coding RNA LUCAT1 Promotes Progression of Thyroid Carcinoma by Reinforcing ADAM10 Expression Through Sequestering microRNA-493.
miR-365 targets ADAM10 and suppresses the cell growth and metastasis of hepatocellular carcinoma.
Novel role of APP cleavage by ADAM10 for breast cancer metastasis.
Overexpression of A disintegrin and metalloprotease 10 promotes tumor proliferation, migration and poor prognosis in hypopharyngeal squamous cell carcinoma.
Overexpression of ADAM10 in oral squamous cell carcinoma with metastases.
PAX2 Regulates ADAM10 Expression and Mediates Anchorage-Independent Cell Growth of Melanoma Cells.
PITPNC1 Recruits RAB1B to the Golgi Network to Drive Malignant Secretion.
Potential Onco-Suppressive Role of miR122 and miR144 in Uveal Melanoma through ADAM10 and C-Met Inhibition.
Proteolytic release of the p75NTR intracellular domain by ADAM10 promotes metastasis and resistance to anoikis.
Reciprocal effects between microRNA-140-5p and ADAM10 suppress migration and invasion of human tongue cancer cells.
Retracted: Downregulation of ADAM10 expression inhibits metastasis and invasiveness of human hepatocellular carcinoma HepG2 cells.
Silencing ADAM10 inhibits the in vitro and in vivo growth of hepatocellular carcinoma cancer cells.
The transcription factor PAX2 regulates ADAM10 expression in renal cell carcinoma.
Transcriptional control of PAX4-regulated miR-144/451 modulates metastasis by suppressing ADAMs expression.
Trop-2 cleavage by ADAM10 is an activator switch for cancer growth and metastasis.
Tspan5 promotes epithelial-mesenchymal transition and tumour metastasis of hepatocellular carcinoma by activating Notch signalling.
Upregulated expression levels of ADAM10 and EGFR and downregulated expression levels of E-cadherin in hepatocellular carcinomas.
[miR-140-5p affects the migration and invasion of hypopharyngeal carcinoma cells by downregulating ADAM10 expression].
Neoplasms
?2-AR activation promotes cleavage and nuclear translocation of Her2 and metastatic potential of cancer cells.
A Disintegrin and Metalloproteinase 9 (ADAM9) in Advanced Hepatocellular Carcinoma and Their Role as a Biomarker During Hepatocellular Carcinoma Immunotherapy.
A disintegrin and metalloproteinase-10 (ADAM-10) mediates DN30 antibody-induced shedding of the met surface receptor.
A novel pan-cancer biomarker plasma heat shock protein 90alpha and its diagnosis determinants in clinic.
A-Disintegrin and Metalloprotease (ADAM) 10 and 17 promote self-renewal of brain tumor sphere forming cells.
Aberrant ADAM10 expression correlates with osteosarcoma progression.
Activation of epidermal growth factor receptor signaling by the prostaglandin E(2) receptor EP4 pathway during gastric tumorigenesis.
Activation of microRNA-494-targeting Bmi1 and ADAM10 by silibinin ablates cancer stemness and predicts favourable prognostic value in head and neck squamous cell carcinomas.
ADAM 10 is associated with gastric cancer progression and prognosis of patients.
ADAM proteases: Emerging role and targeting of the non-catalytic domains.
ADAM-10 and ADAM-17 in the inflamed human CNS.
ADAM-17 expression is enhanced by FoxM1 and is a poor prognostic sign in gastric carcinoma.
ADAM-17 is a poor prognostic indicator for patients with hilar cholangiocarcinoma and is regulated by FoxM1.
ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance.
ADAM10 as a target for anti-cancer therapy.
ADAM10 as a therapeutic target for cancer and inflammation.
ADAM10 Evens Out the Double-Edged Sword of Radiotherapy in Pancreatic Cancer.
ADAM10 is overexpressed in human hepatocellular carcinoma and contributes to the proliferation, invasion and migration of HepG2 cells.
ADAM10 is the constitutive functional sheddase of CD44 in human melanoma cells.
ADAM10 mediates malignant pleural mesothelioma invasiveness.
ADAM10 mediates the cell invasion and metastasis of human esophageal squamous cell carcinoma via regulation of E-cadherin activity.
ADAM10 new selective inhibitors reduce NKG2D ligand release sensitizing Hodgkin lymphoma cells to NKG2D-mediated killing.
ADAM10 overexpression confers resistance to doxorubicin-induced apoptosis in hepatocellular carcinoma.
ADAM10 promotes cell growth, migration, and invasion in osteosarcoma via regulating E-cadherin/?-catenin signaling pathway and is regulated by miR-122-5p.
ADAM10 promotes pituitary adenoma cell migration by regulating cleavage of CD44 and L1.
ADAM10 regulates proliferation, invasion, and chemoresistance of bladder cancer cells.
ADAM10 Sheddase Activity is a Potential Lung-Cancer Biomarker.
ADAM10 Site-Dependent Biology: Keeping Control of a Pervasive Protease.
ADAM10: a new player in breast cancer progression?
ADAM17 but not ADAM10 mediates tumor necrosis factor-alpha and L-selectin shedding from leukocyte membranes.
ADAMs family members as amyloid precursor protein alpha-secretases.
ADAMs in cancer cell proliferation and progression.
Aging-related early changes in markers of ventricular and matrix remodeling after reperfused ST-segment elevation myocardial infarction in the canine model: effect of early therapy with an angiotensin II type 1 receptor blocker.
An activated form of ADAM10 is tumor selective and regulates cancer stem-like cells and tumor growth.
An arginine stretch limits ADAM10 exit from the endoplasmic reticulum.
Arginine vasopressin attenuates the effects of TNF-? in aortic endothelial cells by inducing ectodomain shedding of TNF receptor 1.
BACE1- and BACE2-expressing human cells: characterization of beta-amyloid precursor protein-derived catabolites, design of a novel fluorimetric assay, and identification of new in vitro inhibitors.
Bone morphogenetic protein 15 and fibroblast growth factor 10 enhance cumulus expansion, glucose uptake, and expression of genes in the ovulatory cascade during in vitro maturation of bovine cumulus-oocyte complexes.
Cell-matrix interaction via CD44 is independently regulated by different metalloproteinases activated in response to extracellular Ca(2+) influx and PKC activation.
Cellular sheddases are induced by Merkel cell polyomavirus small tumour antigen to mediate cell dissociation and invasiveness.
CircFOXM1 silencing represses cell proliferation, migration and invasion by regulating miR-515-5p/ADAM10 axis in prostate cancer.
Constitutive activation of metalloproteinase ADAM10 in mantle cell lymphoma promotes cell growth and activates the TNF{alpha}/NF{kappa}B pathway.
Constitutive alpha-secretase cleavage of the beta-amyloid precursor protein in the furin-deficient LoVo cell line: involvement of the pro-hormone convertase 7 and the disintegrin metalloprotease ADAM10.
CXCL16 Is Expressed in Podocytes and Acts as a Scavenger Receptor for Oxidized Low-Density Lipoprotein.
Dendritic cells from aged subjects contribute to chronic airway inflammation by activating bronchial epithelial cells under steady state.
Developmental expression of metalloproteases ADAM 9, 10, and 17 becomes restricted to divergent pancreatic compartments.
Differential surface expression of ADAM10 and ADAM17 on human T lymphocytes and tumor cells.
Discovery of a new selective inhibitor of A Disintegrin And Metalloprotease 10 (ADAM-10) able to reduce the shedding of NKG2D ligands in Hodgkin's lymphoma cell models.
Distinct ADAM metalloproteinases regulate G protein-coupled receptor-induced cell proliferation and survival.
Drosophila TIMP is a potent inhibitor of MMPs and TACE: similarities in structure and function to TIMP-3.
Editorial: ADAM10 in Cancer Immunology and Autoimmunity: More Than a Simple Biochemical Scissor.
Effects of ADAM10 upregulation on progression, migration, and prognosis of nasopharyngeal carcinoma.
EGF promotes the shedding of soluble E-cadherin in an ADAM10-dependent manner in prostate epithelial cells.
Elevated serum HER-2 predicts poor prognosis in breast cancer and is correlated to ADAM10 expression.
Endostatin and irradiation modifies the activity of ADAM10 and neprilysin in breast cancer cells.
Engagement of CD44 promotes Rac activation and CD44 cleavage during tumor cell migration.
Enhanced antitumor activity of gemcitabine by polysaccharide-induced NK cell activation and immune cytotoxicity reduction in vitro/vivo.
Enhanced expression of CD31/platelet endothelial cell adhesion molecule 1 (PECAM1) correlates with hypoxia inducible factor-1 alpha (HIF-1?) in human glioblastoma multiforme.
Enhancing ?-secretase Processing for Alzheimer's Disease-A View on SFRP1.
Enoxaparin prevents CXCL16/ADAM10-mediated cisplatin renal toxicity: Role of the coagulation system and the transcriptional factor NF-?B.
Expression of A disintegrin and metalloprotease 10 in pancreatic carcinoma.
Expression of a-disintegrin and metalloproteinase 10 correlates with grade of malignancy in human glioma.
Expression of ADAM Proteases in Bladder Cancer Patients with BCG Failure: A Pilot Study.
Expression of ADAM10, Fas, FasL and Soluble FasL in Patients with Oral Squamous Cell Carcinoma (OSCC) and their Association with Clinical-Pathological Parameters.
Expression of ADAMs (a disintegrin and metalloproteases) and TIMP-3 (tissue inhibitor of metalloproteinase-3) in human prostatic adenocarcinomas.
Expression of the disintegrin metalloprotease, ADAM-10, in prostate cancer and its regulation by dihydrotestosterone, insulin-like growth factor I, and epidermal growth factor in the prostate cancer cell model LNCaP.
Fendiline inhibits proliferation and invasion of pancreatic cancer cells by interfering with ADAM10 activation and ?-catenin signaling.
High percentage of ADAM-10 positive melanoma cells correlates with paucity of tumor-infiltrating lymphocytes but does not predict prognosis in cutaneous melanoma patients.
Human metalloprotease-disintegrin Kuzbanian regulates sympathoadrenal cell fate in development and neoplasia.
Human renal cancer cells express a novel membrane-bound interleukin-15 that induces, in response to the soluble interleukin-15 receptor alpha chain, epithelial-to-mesenchymal transition.
Huperzine A regulates amyloid precursor protein processing via protein kinase C and mitogen-activated protein kinase pathways in neuroblastoma SK-N-SH cells over-expressing wild type human amyloid precursor protein 695.
Hypoxia induces escape from innate immunity in cancer cells via increased expression of ADAM10: role of nitric oxide.
Hypoxia-induced shedding of MICA and HIF1A-mediated immune escape of pancreatic cancer cells from NK cells: role of circ_0000977/miR-153 axis.
Identification of ADAM10 as a Major Source of HER2 Ectodomain Sheddase Activity in HER2 Overexpressing Breast Cancer Cells.
Immunoprofiles of 11 biomarkers using tissue microarrays identify prognostic subgroups in colorectal cancer.
Impact of ADAM10 gene polymorphisms on hepatocellular carcinoma development and clinical characteristics.
Improved Synthesis of ADAM10 Inhibitor GI254023X.
Increased expression of tumor necrosis factor-alpha converting enzyme and tumor necrosis factor-alpha in peripheral blood mononuclear cells in patients with advanced congestive heart failure.
Induction of ADAM10 by Radiation Therapy Drives Fibrosis, Resistance, and Epithelial-to-Mesenchyal Transition in Pancreatic Cancer.
Inhibitors of A Disintegrin And Metalloproteinases-10 reduce Hodgkin lymphoma cell growth in 3D microenvironments and enhance brentuximab-vedotin effect.
Interleukin-11-driven gastric tumourigenesis is independent of trans-signalling.
Involvement of a disintegrin and metalloproteinase 10 and 17 in shedding of tumor necrosis factor-alpha.
Ionizing radiation increases the endothelial permeability and the transendothelial migration of tumor cells through ADAM10-activation and subsequent degradation of VE-cadherin.
Knockdown of ADAM10 inhibits migration and invasion of fibroblast-like synoviocytes in rheumatoid arthritis.
L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas.
LC-MS Based Cleavage Site Profiling of the Proteases ADAM10 and ADAM17 Using Proteome-Derived Peptide Libraries.
Localization of tumour necrosis factor-alpha converting enzyme in normal human skin.
Mechanisms Of Hypoxia-Induced Immune Escape In Cancer And Their Regulation By Nitric Oxide.
Mesenchymal stem cells: "repair cells" that serve wounds and cancer?
Metalloprotease inhibitor profiles of human ADAM8 in vitro and in cell-based assays.
Metalloproteinases ADAM10 and ADAM17 Mediate Migration and Differentiation in Glioblastoma Sphere-Forming Cells.
Metastasis-associated C4.4A, a GPI-anchored protein cleaved by ADAM10 and ADAM17.
MicroRNA-655-3p functions as a tumor suppressor by regulating ADAM10 and ?-catenin pathway in Hepatocellular Carcinoma.
miR-320a modulates cell growth and chemosensitivity via regulating ADAM10 in gastric cancer.
miR-448 suppressed gastric cancer proliferation and invasion by regulating ADAM10.
miR-449a inhibits proliferation and invasion by regulating ADAM10 in hepatocellular carcinoma.
MiR-449a regulates the cell migration and invasion of human non-small cell lung carcinoma by targeting ADAM10.
Modification of proteolytic activity matrix analysis (PrAMA) to measure ADAM10 and ADAM17 sheddase activities in cell and tissue lysates.
Modulation of Immune Responses by Platelet-Derived ADAM10.
Molecular Pathways: Receptor Ectodomain Shedding in Treatment, Resistance, and Monitoring of Cancer.
NKG2D Ligand Shedding in Response to Stress: Role of ADAM10.
Noncanonical Activation of Notch1 Protein by Membrane Type 1 Matrix Metalloproteinase (MT1-MMP) Controls Melanoma Cell Proliferation.
Nuclear translocation of ADAM-10 contributes to the pathogenesis and progression of human prostate cancer.
Overexpression of A disintegrin and metalloprotease 10 promotes tumor proliferation, migration and poor prognosis in hypopharyngeal squamous cell carcinoma.
Overexpression of tumour necrosis factor-alpha-converting enzyme in psoriasis.
P2Y2 nucleotide receptors mediate metalloprotease-dependent phosphorylation of epidermal growth factor receptor and ErbB3 in human salivary gland cells.
Platelet-Derived Exosomal MicroRNA-25-3p Inhibits Coronary Vascular Endothelial Cell Inflammation Through Adam10 via the NF-?B Signaling Pathway in ApoE-/- Mice.
Platelet-mediated shedding of NKG2D ligands impairs NK cell immune-surveillance of tumor cells.
Protease Cargo in Circulating Exosomes of Breast Cancer and Ovarian Cancer Patients
Proteolytic cleavage of amyloid precursor protein by ADAM10 mediates proliferation and migration in breast cancer.
Proteolytic release of the p75NTR intracellular domain by ADAM10 promotes metastasis and resistance to anoikis.
Proteomic analysis of silenced cathepsin B expression suggests non-proteolytic cathepsin B functionality.
Reciprocal effects between microRNA-140-5p and ADAM10 suppress migration and invasion of human tongue cancer cells.
Regulation of ADAM10 by the TspanC8 Family of Tetraspanins and Their Therapeutic Potential.
Regulation of the trafficking and the function of the metalloprotease ADAM10 by tetraspanins.
Relationships between serum HER2 ECD, TIMP-1 and clinical outcomes in Taiwanese breast cancer.
Role of ADAMs in cancer formation and progression.
Scissor sisters: regulation of ADAM10 by the TspanC8 tetraspanins.
SEP enhanced the antitumor activity of 5-fluorouracil by up-regulating NKG2D/MICA and reversed immune suppression via inhibiting ROS and caspase-3 in mice.
Serological immune response against ADAM10 pro-domain is associated with favourable prognosis in stage III colorectal cancer patients.
SFRPs act as negative modulators of ADAM10 to regulate retinal neurogenesis.
Shedding of endogenous MHC class I-related chain molecules A and B (MICA and MICB) from different human tumor entities: Heterogeneous involvement of the a disintegrin and metalloproteases 10 and 17 (ADAM10 and ADAM17).
Silencing ADAM10 inhibits the in vitro and in vivo growth of hepatocellular carcinoma cancer cells.
Soluble CXCL16 promotes TNF-?-induced apoptosis in DLBCL via the AMAD10-NF-?B regulatory feedback loop.
Specific ADAM10 inhibitors localize in exosome-like vesicles released by Hodgkin lymphoma and stromal cells and prevent sheddase activity carried to bystander cells.
SRC fine-tunes ADAM10 shedding activity to promote pituitary adenoma cell progression.
Stimulated release and functional activity of surface expressed metalloproteinase ADAM17 in exosomes.
Stimulation of platelet-derived growth factor receptor beta (PDGFRbeta) activates ADAM17 and promotes metalloproteinase-dependent cross-talk between the PDGFRbeta and epidermal growth factor receptor (EGFR) signaling pathways.
Synthesis and in vitro Evaluation of ADAM10 and ADAM17 Highly Selective Bioimaging Probes.
Systemic presence and tumor-growth promoting effect of ovarian carcinoma released exosomes.
Targeting ADAM10 in Cancer and Autoimmunity.
Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma.
Tetraspanin CD9 interacts with ?-secretase to enhance its oncogenic function in pancreatic cancer.
The "A Disintegrin And Metalloproteases" ADAM10 and ADAM17: Novel drug targets with therapeutic potential?
The ADAM10 prodomain is a specific inhibitor of ADAM10 proteolytic activity and inhibits cellular shedding events.
The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?
The association of the expression of miR-122-5p and its target ADAM10 with human breast cancer.
The disintegrin ADAM9 indirectly contributes to the physiological processing of cellular prion by modulating ADAM10 activity.
The disintegrin-metalloproteinases ADAM 10, 12 and 17 are upregulated in invading peripheral tumor cells of basal cell carcinomas.
The disintegrins ADAM10 and TACE contribute to the constitutive and phorbol ester-regulated normal cleavage of the cellular prion protein.
The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer.
The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3.
The metalloproteinase ADAM10 requires its activity to sustain surface expression.
The metalloproteinase ADAM10: A useful therapeutic target?
The role of ADAM10 and ADAM17 in the ectodomain shedding of angiotensin converting enzyme and the amyloid precursor protein.
The role of ADAMs in disease pathophysiology.
The tetraspanin Tspan15 is an essential subunit of an ADAM10 scissor complex.
The transcription factor PAX2 regulates ADAM10 expression in renal cell carcinoma.
The TspanC8 subgroup of tetraspanins interacts with A disintegrin and metalloprotease 10 (ADAM10) and regulates its maturation and cell surface expression.
Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling.
TNF? drives pulmonary arterial hypertension by suppressing the BMP type-II receptor and altering NOTCH signalling.
Transcriptional control of PAX4-regulated miR-144/451 modulates metastasis by suppressing ADAMs expression.
Transcriptional repression of the ectodomain sheddase ADAM10 by TBX2 and potential implication for Alzheimer's disease.
Triptolide: An inhibitor of a disintegrin and metalloproteinase 10 (ADAM10) in cancer cells.
Trop-2 cleavage by ADAM10 is an activator switch for cancer growth and metastasis.
Tspan5 promotes epithelial-mesenchymal transition and tumour metastasis of hepatocellular carcinoma by activating Notch signalling.
TspanC8 Tetraspanins and A Disintegrin and Metalloprotease 10 (ADAM10) Interact via Their Extracellular Regions: EVIDENCE FOR DISTINCT BINDING MECHANISMS FOR DIFFERENT TspanC8 PROTEINS.
Tumor cell-derived Timp-1 is necessary for maintaining metastasis-promoting Met-signaling via inhibition of Adam-10.
Tumor necrosis factor-?-induced a disintegrin and metalloprotease 10 increases apoptosis resistance in prostate cancer cells.
Tumor suppressor cell adhesion molecule 1 (CADM1) is cleaved by a disintegrin and metalloprotease 10 (ADAM10) and subsequently cleaved by ?-secretase complex.
Tumor-associated MICA is shed by ADAM proteases.
Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients.
Upregulated expression levels of ADAM10 and EGFR and downregulated expression levels of E-cadherin in hepatocellular carcinomas.
Upregulation of the alpha-secretase ADAM10--risk or reason for hope?
Vitamin B12 deficiency reduces proliferation and promotes differentiation of neuroblastoma cells and up-regulates PP2A, proNGF, and TACE.
Vitamin D-induced ectodomain shedding of TNF receptor 1 as a nongenomic action: D3 vs D2 derivatives.
[Generation and characterization of the adult neuron-specific ADAM10 knock-out mice].
[miR-140-5p affects the migration and invasion of hypopharyngeal carcinoma cells by downregulating ADAM10 expression].
Nephritis
ADAM10-Mediated Ectodomain Shedding Is an Essential Driver of Podocyte Damage.
Nephrotic Syndrome
oxLDL promotes podocyte migration by regulating CXCL16, ADAM10 and ACTN4.
Nervous System Diseases
Neuronal ADAM10 Promotes Outgrowth of Small-Caliber Myelinated Axons in the Peripheral Nervous System.
Regulation of ADAM10 by MicroRNA-23a Contributes to Epileptogenesis in Pilocarpine-Induced Status Epilepticus Mice.
Neuralgia
Neuron-Derived ADAM10 Production Stimulates Peripheral Nerve Injury-Induced Neuropathic Pain by Cleavage of E-Cadherin in Satellite Glial Cells.
Neuroblastoma
Acetylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in neuroblastoma cell lines.
Acitretin, an Enhancer of Alpha-Secretase Expression, Crosses the Blood-Brain Barrier and Is Not Eliminated by P-Glycoprotein.
ADAM10 expression and promoter haplotype in Alzheimer's disease.
ADAM10 Plasma and CSF Levels Are Increased in Mild Alzheimer's Disease.
ADAM9 inhibition increases membrane activity of ADAM10 and controls ?-secretase processing of amyloid precursor protein.
Alpha-secretase as a therapeutic target.
Chronic hypoxia in the human neuroblastoma SH-SY5Y causes reduced expression of the putative alpha-secretases, ADAM10 and TACE, without altering their mRNA levels.
Extract of Caragana sinica as a potential therapeutic option for increasing alpha-secretase gene expression.
Phenanthroline impairs ?APP processing and expression, increases p53 protein levels and induces cell cycle arrest in human neuroblastoma cells.
PI3-K- and PKC-dependent up-regulation of APP processing enzymes by retinoic acid.
PKC Activation Counteracts ADAM10 Deficit in HuD-Silenced Neuroblastoma Cells.
Proteolytic shedding of the prion protein via activation of metallopeptidase ADAM10 reduces cellular binding and toxicity of amyloid-? oligomers.
Retinoids as a perspective in treatment of Alzheimer's disease.
Role of ADAMs in the ectodomain shedding and conformational conversion of the prion protein.
Shedding of the amyloid precursor protein-like protein APLP2 by disintegrin-metalloproteinases.
Stimulation of Non-Amyloidogenic Processing of Amyloid-? Protein Precursor by Cryptotanshinone Involves Activation and Translocation of ADAM10 and PKC-?
Targeting ADAM10 to lipid rafts in neuroblastoma SH-SY5Y cells impairs amyloidogenic processing of the amyloid precursor protein.
Tetraspanin 3: A central endocytic membrane component regulating the expression of ADAM10, presenilin and the amyloid precursor protein.
The expression of the nicotinic acetylcholine receptor ?3 subunit in the brains of patients with Alzheimer's disease and its effects on ?- and ?-secretases and Notch signal transduction in SH-SY5Y cells.
Transcriptional repression of the ectodomain sheddase ADAM10 by TBX2 and potential implication for Alzheimer's disease.
Up-regulation of the {alpha}-secretase ADAM10 by retinoic acid receptors and acitretin.
Neurodegenerative Diseases
ADAM10 as a therapeutic target for brain diseases: from developmental disorders to Alzheimer's disease.
Alpha-Secretase ADAM10 Regulation: Insights into Alzheimer's Disease Treatment.
Ionizing radiation reduces ADAM10 expression in brain microvascular endothelial cells undergoing stress-induced senescence.
LC-MS Based Cleavage Site Profiling of the Proteases ADAM10 and ADAM17 Using Proteome-Derived Peptide Libraries.
PKC Activation Counteracts ADAM10 Deficit in HuD-Silenced Neuroblastoma Cells.
Regulation of Alpha-Secretase ADAM10 In vitro and In vivo: Genetic, Epigenetic, and Protein-Based Mechanisms.
Roles of endoproteolytic ?-cleavage and shedding of the prion protein in neurodegeneration.
Scissor sisters: regulation of ADAM10 by the TspanC8 tetraspanins.
The "A Disintegrin And Metalloproteases" ADAM10 and ADAM17: Novel drug targets with therapeutic potential?
Upregulation of the alpha-secretase ADAM10--risk or reason for hope?
Neuroinflammatory Diseases
ADAM10 suppresses demyelination and reduces seizure susceptibility in cuprizone-induced demyelination model.
Effects of neuron-specific ADAM10 modulation in an in vivo model of acute excitotoxic stress.
Gallic Acid is a Dual ?/?-Secretase Modulator that Reverses Cognitive Impairment and Remediates Pathology in Alzheimer Mice.
Metalloprotease Adam10 suppresses epilepsy through repression of hippocampal neuroinflammation.
The Gut-Brain Axis in Autism Spectrum Disorder: A Focus on the Metalloproteases ADAM10 and ADAM17.
Nevus
PAX2 Regulates ADAM10 Expression and Mediates Anchorage-Independent Cell Growth of Melanoma Cells.
Obesity
The effect of age and obesity on platelet amyloid precursor protein processing and plasma markers of oxidative stress and inflammation.
Osteoarthritis
ADAM-10 protein is present in human articular cartilage primarily in the membrane-bound form and is upregulated in osteoarthritis and in response to IL-1alpha in bovine nasal cartilage.
Osteosarcoma
Aberrant ADAM10 expression correlates with osteosarcoma progression.
ADAM10 promotes cell growth, migration, and invasion in osteosarcoma via regulating E-cadherin/?-catenin signaling pathway and is regulated by miR-122-5p.
Ovarian Neoplasms
Ectodomain shedding of the cell adhesion molecule Nectin-4 in ovarian cancer is mediated by ADAM10 and ADAM17.
Metalloproteinases at the surface of small extrcellular vesicles in advanced ovarian cancer: Relationships with ascites volume and peritoneal canceromatosis index.
Protease Cargo in Circulating Exosomes of Breast Cancer and Ovarian Cancer Patients
Proteases and their inhibitors as prognostic factors for high-grade serous ovarian cancer.
Pancreatic Neoplasms
A Soluble Form of the Giant Cadherin Fat1 Is Released from Pancreatic Cancer Cells by ADAM10 Mediated Ectodomain Shedding.
ADAM10 Evens Out the Double-Edged Sword of Radiotherapy in Pancreatic Cancer.
Expression of A disintegrin and metalloprotease 10 in pancreatic carcinoma.
Fendiline inhibits proliferation and invasion of pancreatic cancer cells by interfering with ADAM10 activation and ?-catenin signaling.
Induction of ADAM10 by Radiation Therapy Drives Fibrosis, Resistance, and Epithelial-to-Mesenchyal Transition in Pancreatic Cancer.
Pancreatitis, Chronic
Expression of A disintegrin and metalloprotease 10 in pancreatic carcinoma.
Parkinson Disease
Association of ADAM10 gene variants with sporadic Parkinson's disease in Chinese Han population.
Cerebrospinal fluid A?42 levels and APP processing pathway genes in Parkinson's disease.
Pemphigus
The involvement of ADAM10 in mucocutaneous pemphigus vulgaris acantholysis depends on the autoantibody profile in each patient.
Pituitary Neoplasms
ADAM10 promotes pituitary adenoma cell migration by regulating cleavage of CD44 and L1.
SRC fine-tunes ADAM10 shedding activity to promote pituitary adenoma cell progression.
Pneumonia
A potential new target for asthma therapy: A Disintegrin and Metalloprotease 10 (ADAM10) involvement in murine experimental asthma.
A Staphylococcus aureus pore-forming toxin subverts the activity of ADAM10 to cause lethal infection in mice.
ADAM10 Partially Protects Mice against Influenza Pneumonia by Suppressing Specific Myeloid Cell Population.
Tissue-specific patterning of host innate immune responses by Staphylococcus aureus ?-toxin.
Pneumonia, Staphylococcal
Immunopathogenesis of Staphylococcus aureus pulmonary infection.
Polycystic Kidney, Autosomal Dominant
Polycystin-1 and G?12 regulate the cleavage of E-cadherin in kidney epithelial cells.
Polymyositis
The cell-specific expression of metalloproteinase-disintegrins (ADAMs) in inflammatory myopathies.
Polyuria
Adam10 Mediates the Choice between Principal Cells and Intercalated Cells in the Kidney.
Pre-Eclampsia
Increased ADAM10 expression in preeclamptic placentas is associated with decreased expression of hydrogen sulfide production enzymes.
Protein misfolding, congophilia, oligomerization, and defective amyloid processing in preeclampsia.
Protocadherin-12 cleavage is a regulated process mediated by ADAM-10. Evidence of shedding upregulation in preeclampsia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Crucial role of the Rap G protein signal in Notch activation and leukemogenicity of T-cell acute lymphoblastic leukemia.
Redundancy and specificity of the metalloprotease system mediating oncogenic NOTCH1 activation in T-ALL.
Prion Diseases
Scissor sisters: regulation of ADAM10 by the TspanC8 tetraspanins.
Shedding light on prion disease.
Structural and mechanistic aspects influencing the ADAM10-mediated shedding of the prion protein.
The sheddase ADAM10 is a potent modulator of prion disease.
TREM2 expression in the brain and biological fluids in prion diseases.
Prostatic Hyperplasia
Expression of ADAMs (a disintegrin and metalloproteases) and TIMP-3 (tissue inhibitor of metalloproteinase-3) in human prostatic adenocarcinomas.
Prostatic Neoplasms
Expression of the disintegrin metalloprotease, ADAM-10, in prostate cancer and its regulation by dihydrotestosterone, insulin-like growth factor I, and epidermal growth factor in the prostate cancer cell model LNCaP.
Nuclear translocation of ADAM-10 contributes to the pathogenesis and progression of human prostate cancer.
Tumor necrosis factor-?-induced a disintegrin and metalloprotease 10 increases apoptosis resistance in prostate cancer cells.
Purpura Fulminans
An ADAM-10 dependent EPCR shedding links meningococcal interaction with endothelial cells to purpura fulminans.
Purpura, Thrombocytopenic, Idiopathic
Increased ADAM10 expression in patients with immune thrombocytopenia.
Radiation Fibrosis Syndrome
ADAM10 Evens Out the Double-Edged Sword of Radiotherapy in Pancreatic Cancer.
Renal Insufficiency, Chronic
PAX2 may induce ADAM10 expression in renal tubular epithelial cells and contribute to epithelial-to-mesenchymal transition.
Therapeutic impact of rHuEPO on abnormal platelet APP, BACE 1, presenilin 1, ADAM 10 and A? expressions in chronic kidney disease patients with cognitive dysfunction like Alzheimer's disease: A pilot study.
Reoviridae Infections
A functional role for ADAM10 in human immunodeficiency virus type-1 replication.
Retroviridae Infections
[miR-25-3p down-regulates the expression of ADAM10 to inhibit the differentiation of P19 cells into cardiomyocytes by blocking the Notch signaling pathway].
Rhinitis
Expression of ADAM17 and ADAM10 in nasal polyps.
Rhinitis, Allergic
Expression profile of ADAM10 and ADAM17 in allergic rhinitis.
Scrapie
Apparent Reduction of ADAM10 in Scrapie-Infected Cultured Cells and in the Brains of Scrapie-Infected Rodents.
Influence of ADAM10 on prion protein processing and scrapie infectiosity in vivo.
Seizures
ADAM10 suppresses demyelination and reduces seizure susceptibility in cuprizone-induced demyelination model.
Effects of neuron-specific ADAM10 modulation in an in vivo model of acute excitotoxic stress.
Metalloprotease Adam10 suppresses epilepsy through repression of hippocampal neuroinflammation.
Postnatal disruption of the disintegrin/metalloproteinase ADAM10 in brain causes epileptic seizures, learning deficits, altered spine morphology, and defective synaptic functions.
Promoter Variants of the ADAM10 Gene and Their Roles in Temporal Lobe Epilepsy.
Regulation of ADAM10 by MicroRNA-23a Contributes to Epileptogenesis in Pilocarpine-Induced Status Epilepticus Mice.
Stage-dependent involvement of ADAM10 and its significance in epileptic seizures.
Sepsis
A Functional Polymorphism-Mediated Disruption of EGR1/ADAM10 Pathway Confers the Risk of Sepsis Progression.
ADAM10 mediates vascular injury induced by Staphylococcus aureus ?-hemolysin.
An ADAM10 promoter polymorphism is a functional variant in severe sepsis patients and confers susceptibility to the development of sepsis.
miR-23b Negatively Regulates Sepsis-Induced Inflammatory Responses by Targeting ADAM10 in Human THP-1 Monocytes.
Soluble VE-cadherin is involved in endothelial barrier breakdown in systemic inflammation and sepsis.
Synergistic Action of Staphylococcus aureus ?-Toxin on Platelets and Myeloid Lineage Cells Contributes to Lethal Sepsis.
Shock, Septic
Plasma soluble Tim-3 emerges as an inhibitor in sepsis: sepsis contrary to membrane Tim-3 on monocytes.
Squamous Cell Carcinoma of Head and Neck
Activation of microRNA-494-targeting Bmi1 and ADAM10 by silibinin ablates cancer stemness and predicts favourable prognostic value in head and neck squamous cell carcinomas.
ADAM 10 is over expressed in oral squamous cell carcinoma and contributes to invasive behaviour through a functional association with ?v?6 integrin.
Expression of ADAM10, Fas, FasL and Soluble FasL in Patients with Oral Squamous Cell Carcinoma (OSCC) and their Association with Clinical-Pathological Parameters.
Overexpression of A disintegrin and metalloprotease 10 promotes tumor proliferation, migration and poor prognosis in hypopharyngeal squamous cell carcinoma.
Overexpression of ADAM10 in oral squamous cell carcinoma with metastases.
Rare driver mutations in head and neck squamous cell carcinomas converge on NOTCH signaling.
Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding.
Targeting the sheddase activity of ADAM17 by an anti-ADAM17 antibody D1(A12) inhibits head and neck squamous cell carcinoma cell proliferation and motility via blockage of bradykinin induced HERs transactivation.
Upregulation of ADAM10 in oral squamous cell carcinoma and its correlation with EGFR, neoangiogenesis and clinicopathologic factors.
Staphylococcal Infections
Tissue-specific patterning of host innate immune responses by Staphylococcus aureus ?-toxin.
Starvation
Autophagy-Dependent Increased ADAM10 Mature Protein Induced by TFEB Overexpression Is Mediated Through PPAR?.
Status Epilepticus
ADAM9, ADAM10, and ADAM15 mRNA levels in the rat brain after kainic acid-induced status epilepticus.
Regulation of ADAM10 by MicroRNA-23a Contributes to Epileptogenesis in Pilocarpine-Induced Status Epilepticus Mice.
Stomach Neoplasms
ADAM 10 is associated with gastric cancer progression and prognosis of patients.
ADAM-17 expression is enhanced by FoxM1 and is a poor prognostic sign in gastric carcinoma.
EphA8 acts as an oncogene and contributes to poor prognosis in gastric cancer via regulation of ADAM10.
miR-320a modulates cell growth and chemosensitivity via regulating ADAM10 in gastric cancer.
miR-448 suppressed gastric cancer proliferation and invasion by regulating ADAM10.
Stroke
Scissor sisters: regulation of ADAM10 by the TspanC8 tetraspanins.
Tauopathies
Associations of Alzheimer's disease risk variants with gene expression, amyloidosis, tauopathy, and neurodegeneration.
Thromboangiitis Obliterans
ADAM10 inhibits the interaction between IL-17 and HMGB1 in Buerger's disease.
Alleviation of A disintegrin and metalloprotease 10 (ADAM10) on thromboangiitis obliterans involves the HMGB1/RAGE/ NF-?B pathway.
Thrombosis
Upregulated expression levels of ADAM10 and EGFR and downregulated expression levels of E-cadherin in hepatocellular carcinomas.
Thyroid Neoplasms
Long Non-Coding RNA LUCAT1 Promotes Progression of Thyroid Carcinoma by Reinforcing ADAM10 Expression Through Sequestering microRNA-493.
Tongue Neoplasms
Reciprocal effects between microRNA-140-5p and ADAM10 suppress migration and invasion of human tongue cancer cells.
Triple Negative Breast Neoplasms
ADAM10 is involved in the oncogenic process and chemo-resistance of triple-negative breast cancer via regulating Notch1 signaling pathway, CD44 and PrPc.
miR-365 inhibits cell invasion and migration of triple negative breast cancer through ADAM10.
Proteolytic processing of PD-L1 by ADAM proteases in breast cancer cells.
Urinary Bladder Neoplasms
ADAM10 regulates proliferation, invasion, and chemoresistance of bladder cancer cells.
Uterine Cervical Neoplasms
LncRNA SNHG20 promotes cell proliferation and invasion via miR-140-5p-ADAM10 axis in cervical cancer.
Varicose Veins
Increased Levels of Metalloproteinase 10 and Hemostatic Markers in Patients With Noncomplicated Primary Varicose Veins.
Vascular Diseases
The Antiatherogenic Effect of Fish Oil in Male Mice Is Associated with a Diminished Release of Endothelial ADAM17 and ADAM10 Substrates.
Vascular System Injuries
ADAM10 mediates vascular injury induced by Staphylococcus aureus ?-hemolysin.
Virus Diseases
ADAM10 Partially Protects Mice against Influenza Pneumonia by Suppressing Specific Myeloid Cell Population.